Symbols / NGNE Stock $27.47 +0.07% Neurogene Inc.

Healthcare • Biotechnology • United States • NGM
NGNE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Rachel L. McMinn Ph.D.
Exch · Country NGM · United States
Market Cap 428.97M
Enterprise Value 168.39M
Income -90.35M
Sales —
FCF (ttm) -46.47M
Book/sh 17.10
Cash/sh 17.27
Employees 131
Insider 10d —
IPO Mar 07, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.20
PEG —
P/S —
P/B 1.61
P/C —
EV/EBITDA -1.68
EV/Sales —
Quick Ratio 16.42
Current Ratio 16.56
Debt/Eq 3.73
LT Debt/Eq —
EPS (ttm) -4.24
EPS next Y -5.28
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-03-24
ROA -20.66%
ROE -31.41%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 15.62M
Shs Float 5.13M
Insider Own 9.00%
Instit Own 108.74%
Short Float 32.17%
Short Ratio 26.23
Short Interest 4.01M
52W High 37.27
vs 52W High -26.29%
52W Low 11.77
vs 52W Low 133.39%
Beta 1.89
Impl. Vol. 1.50%
Rel Volume 0.25
Avg Volume 174.32K
Volume 43.24K
Target (mean) $77.67
Tgt Median $60.00
Tgt Low $46.00
Tgt High $180.00
# Analysts 6
Recom Strong_buy
Prev Close $27.45
Price $27.47
Change 0.07%
About

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$77.67
Mean price target
2. Current target
$27.47
Latest analyst target
3. DCF / Fair value
$-53.56
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$27.47
Low
$46.00
High
$180.00
Mean
$77.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-06 main Canaccord Genuity Buy → Buy $180
2026-02-27 init Canaccord Genuity — → Buy $200
2026-01-26 init LifeSci Capital — → Outperform $50
2026-01-13 reit HC Wainwright & Co. Buy → Buy $70
2025-11-13 main HC Wainwright & Co. Buy → Buy $70
2025-10-31 main HC Wainwright & Co. Buy → Buy $65
2025-10-09 reit HC Wainwright & Co. Buy → Buy $45
2025-06-17 init Craig-Hallum — → Buy $50
2025-06-12 main BMO Capital Outperform → Outperform $26
2025-05-20 main BMO Capital Outperform → Outperform $22
2025-05-16 down Baird Outperform → Neutral $24
2025-05-13 main HC Wainwright & Co. Buy → Buy $45
2025-04-14 main BMO Capital Outperform → Outperform $16
2025-03-25 main Baird Outperform → Outperform $36
2025-03-25 main HC Wainwright & Co. Buy → Buy $50
2024-11-25 reit HC Wainwright & Co. Buy → Buy $55
2024-11-20 main BMO Capital Outperform → Outperform $45
2024-11-19 reit HC Wainwright & Co. Buy → Buy $55
2024-11-12 main Stifel Buy → Buy $60
2024-11-12 main BMO Capital Outperform → Outperform $60
News
RSS: Latest NGNE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-26 CVIJIC CHRISTINE MIKAIL President — 2,558 $21.62 $55,316
2026-03-26 MCMINN RACHEL L. PH.D. Chief Executive Officer — 3,352 $22.07 $73,995
2026-03-26 JORDAN JULIE Officer — 828 $21.89 $18,128
2026-03-13 CVIJIC CHRISTINE MIKAIL President — 4,045 $20.42 $84,176
2026-03-13 COBB STUART Officer — 6,797 $20.41 $141,446
2026-02-27 CVIJIC CHRISTINE MIKAIL Chief Executive Officer — 4,800 $25.11 $120,526
2026-02-20 CVIJIC CHRISTINE MIKAIL President — 22,000 $0.00 $0
2026-02-20 MCMINN RACHEL L. PH.D. Chief Executive Officer — 25,900 $0.00 $0
2026-02-20 JORDAN JULIE Officer — 4,900 $0.00 $0
2026-02-20 COBB STUART Officer — 16,500 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
0.93
0.00
0.00
Operating Revenue
0.00
-100.00%
0.93
0.00
0.00
Operating Expense
103.33
+23.70%
83.53
+50.28%
55.58
-1.65%
56.52
Research And Development
75.01
+23.14%
60.92
+37.22%
44.39
-6.55%
47.51
Selling General And Administration
28.32
+25.22%
22.61
+102.10%
11.19
+24.16%
9.01
General And Administrative Expense
28.32
+25.22%
22.61
+102.10%
11.19
+24.16%
9.01
Salaries And Wages
16.97
+42.46%
11.91
—
—
Other Gand A
11.35
+6.05%
10.70
-4.35%
11.19
+24.16%
9.01
Total Expenses
103.33
+23.70%
83.53
+50.28%
55.58
-1.65%
56.52
Operating Income
-103.33
-25.09%
-82.61
-48.62%
-55.58
+1.65%
-56.52
Total Operating Income As Reported
-103.33
-25.09%
-82.61
-48.62%
-55.58
+1.65%
-56.52
EBITDA
-87.25
-21.38%
-71.89
-117.78%
-33.01
+36.51%
-51.99
Normalized EBITDA
-87.25
-21.38%
-71.89
-45.63%
-49.36
+5.05%
-51.99
Reconciled Depreciation
3.09
-4.77%
3.25
-1.52%
3.30
+3.03%
3.20
EBIT
-90.35
-20.25%
-75.13
-106.95%
-36.30
+34.21%
-55.19
Total Unusual Items
—
0.57
-96.49%
16.36
0.00
Total Unusual Items Excluding Goodwill
—
0.57
-96.49%
16.36
0.00
Special Income Charges
—
0.57
-96.49%
16.36
0.00
Restructuring And Mergern Acquisition
—
-0.57
+96.49%
-16.36
0.00
Net Income
-90.35
-20.24%
-75.14
-106.91%
-36.32
+34.20%
-55.19
Pretax Income
-90.35
-20.24%
-75.14
-106.91%
-36.32
+34.20%
-55.19
Net Non Operating Interest Income Expense
11.54
+36.51%
8.46
+187.68%
2.94
+120.15%
1.33
Interest Expense Non Operating
0.01
-58.33%
0.01
+0.00%
0.01
+500.00%
0.00
Net Interest Income
11.54
+36.51%
8.46
+187.68%
2.94
+120.15%
1.33
Interest Expense
0.01
-58.33%
0.01
+0.00%
0.01
+500.00%
0.00
Interest Income Non Operating
11.55
+36.38%
8.47
+186.92%
2.95
+120.72%
1.34
Interest Income
11.55
+36.38%
8.47
+186.92%
2.95
+120.72%
1.34
Other Income Expense
1.44
+244.37%
-0.99
-106.09%
16.33
+233342.86%
-0.01
Other Non Operating Income Expenses
1.44
+244.37%
-0.99
-3450.00%
-0.03
-300.00%
-0.01
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-90.35
-20.24%
-75.14
-106.91%
-36.32
+34.20%
-55.19
Net Income From Continuing Operation Net Minority Interest
-90.35
-20.24%
-75.14
-106.91%
-36.32
+34.20%
-55.19
Net Income From Continuing And Discontinued Operation
-90.35
-20.24%
-75.14
-106.91%
-36.32
+34.20%
-55.19
Net Income Continuous Operations
-90.35
-20.24%
-75.14
-106.91%
-36.32
+34.20%
-55.19
Normalized Income
-90.35
-20.24%
-75.14
-42.66%
-52.67
+4.56%
-55.19
Net Income Common Stockholders
-90.35
-20.24%
-75.14
-106.91%
-36.32
+34.20%
-55.19
Diluted EPS
—
-4.28
+94.20%
-73.83
-95.32%
-37.80
Basic EPS
—
-4.28
+94.20%
-73.83
-95.32%
-37.80
Basic Average Shares
—
17.57
+3471.51%
0.49
-66.31%
1.46
Diluted Average Shares
—
17.57
+277.22%
4.66
+218.97%
1.46
Diluted NI Availto Com Stockholders
-90.35
-20.24%
-75.14
-106.91%
-36.32
+34.20%
-55.19
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
288.60
-14.04%
335.73
+50.84%
222.57
+103.70%
109.27
Current Assets
271.77
-13.98%
315.92
+57.69%
200.35
+136.49%
84.72
Cash Cash Equivalents And Short Term Investments
269.01
-13.89%
312.40
+58.45%
197.16
+140.37%
82.02
Cash And Cash Equivalents
103.84
-23.97%
136.59
-7.84%
148.21
+80.70%
82.02
Other Short Term Investments
165.17
-6.06%
175.82
+259.20%
48.95
0.00
Receivables
0.46
-29.01%
0.65
+8.00%
0.60
-39.39%
0.99
Other Receivables
0.46
-29.01%
0.65
+8.00%
0.60
-39.39%
0.99
Prepaid Assets
1.94
+2.59%
1.89
+26.27%
1.50
+38.78%
1.08
Current Deferred Assets
0.19
0.00
—
—
Other Current Assets
0.17
-82.87%
0.98
-10.41%
1.09
+73.81%
0.63
Total Non Current Assets
16.83
-15.01%
19.81
-10.88%
22.23
-9.46%
24.55
Net PPE
15.46
-16.39%
18.49
-11.74%
20.95
-14.64%
24.55
Gross PPE
29.57
-0.31%
29.66
+2.42%
28.96
-1.20%
29.31
Accumulated Depreciation
-14.11
-26.30%
-11.17
-39.48%
-8.01
-68.01%
-4.77
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.32
+3.62%
0.30
+5.92%
0.29
-0.69%
0.29
Construction In Progress
0.32
-75.23%
1.31
+458.97%
0.23
-7.14%
0.25
Other Properties
13.51
+6.78%
12.66
-3.13%
13.06
-3.04%
13.47
Leases
15.42
+0.14%
15.40
+0.13%
15.38
+0.51%
15.30
Non Current Accounts Receivable
—
—
0.10
+12.64%
0.09
Other Non Current Assets
1.37
+4.41%
1.31
+3.30%
1.27
—
Total Liabilities Net Minority Interest
23.72
-6.46%
25.36
-30.63%
36.55
-85.67%
255.00
Current Liabilities
16.41
+8.27%
15.16
-34.02%
22.97
+245.41%
6.65
Payables And Accrued Expenses
7.07
+10.81%
6.38
-52.30%
13.38
+451.84%
2.42
Payables
1.95
+46.18%
1.34
-48.54%
2.60
+315.36%
0.62
Accounts Payable
1.95
+46.18%
1.34
-48.54%
2.60
+315.36%
0.62
Current Accrued Expenses
5.12
+1.45%
5.05
-53.21%
10.79
+499.22%
1.80
Pensionand Other Post Retirement Benefit Plans Current
5.07
+16.81%
4.34
-27.29%
5.97
+77.90%
3.36
Current Debt And Capital Lease Obligation
3.70
-9.49%
4.09
+41.92%
2.88
+310.54%
0.70
Current Capital Lease Obligation
3.70
-9.49%
4.09
+41.92%
2.88
+310.54%
0.70
Other Current Liabilities
0.56
+64.91%
0.34
-53.60%
0.74
+341.32%
0.17
Total Non Current Liabilities Net Minority Interest
7.31
-28.36%
10.20
-24.88%
13.58
-94.53%
248.35
Long Term Debt And Capital Lease Obligation
7.25
-28.50%
10.15
-24.12%
13.37
+235.42%
3.99
Long Term Capital Lease Obligation
7.25
-28.50%
10.15
-24.12%
13.37
+235.42%
3.99
Other Non Current Liabilities
0.05
+0.00%
0.05
-74.88%
0.20
—
Preferred Securities Outside Stock Equity
—
—
0.00
-100.00%
244.37
Stockholders Equity
264.89
-14.66%
310.38
+66.85%
186.02
+227.64%
-145.74
Common Stock Equity
264.89
-14.66%
310.38
+66.85%
186.02
+227.64%
-145.74
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
15.49
+4.28%
14.85
+15.84%
12.82
+0.00%
12.82
Ordinary Shares Number
15.49
+4.28%
14.85
+15.84%
12.82
+0.00%
12.82
Additional Paid In Capital
617.54
+7.83%
572.67
+53.46%
373.18
+7220.09%
5.10
Retained Earnings
-352.65
-34.45%
-262.30
-40.15%
-187.15
-24.08%
-150.84
Total Equity Gross Minority Interest
264.89
-14.66%
310.38
+66.85%
186.02
+227.64%
-145.74
Total Capitalization
264.89
-14.66%
310.38
+66.85%
186.02
+227.64%
-145.74
Working Capital
255.36
-15.10%
300.77
+69.57%
177.38
+127.21%
78.07
Invested Capital
264.89
-14.66%
310.38
+66.85%
186.02
+227.64%
-145.74
Total Debt
10.96
-23.04%
14.24
-12.41%
16.25
+246.66%
4.69
Capital Lease Obligations
10.96
-23.04%
14.24
-12.41%
16.25
+246.66%
4.69
Net Tangible Assets
264.89
-14.66%
310.38
+66.85%
186.02
+227.64%
-145.74
Tangible Book Value
264.89
-14.66%
310.38
+66.85%
186.02
+227.64%
-145.74
Notes Receivable
—
—
48.95
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-77.17
-9.31%
-70.60
-37.30%
-51.42
+2.65%
-52.82
Cash Flow From Continuing Operating Activities
-77.17
-9.31%
-70.60
-37.30%
-51.42
+2.65%
-52.82
Net Income From Continuing Operations
-90.35
-20.24%
-75.14
-106.91%
-36.32
+34.20%
-55.19
Depreciation Amortization Depletion
3.09
-4.77%
3.25
-1.52%
3.30
+3.03%
3.20
Depreciation
3.09
-4.77%
3.25
-1.52%
3.30
+3.03%
3.20
Depreciation And Amortization
3.09
-4.77%
3.25
-1.52%
3.30
+3.03%
3.20
Other Non Cash Items
0.05
-95.96%
1.26
+108.05%
-15.69
-2680.92%
0.61
Stock Based Compensation
14.18
+70.47%
8.32
+486.74%
1.42
+13.26%
1.25
Asset Impairment Charge
0.12
+31.87%
0.09
0.00
—
Change In Working Capital
0.27
+104.50%
-5.96
-48.17%
-4.02
-49.28%
-2.69
Change In Prepaid Assets
0.95
+391.13%
-0.33
-200.31%
0.33
-54.47%
0.72
Change In Payables And Accrued Expense
2.29
+180.42%
-2.85
+1.96%
-2.91
-3.78%
-2.80
Change In Accrued Expense
1.67
+160.04%
-2.77
+22.41%
-3.57
-543.42%
0.81
Change In Payable
0.63
+914.29%
-0.08
-111.54%
0.67
+118.49%
-3.61
Change In Account Payable
0.63
+914.29%
-0.08
-111.54%
0.67
+118.49%
-3.61
Change In Other Current Assets
-0.06
+72.51%
-0.21
+72.38%
-0.76
0.00
Change In Other Current Liabilities
-2.92
-13.41%
-2.57
-279.50%
-0.68
-11.15%
-0.61
Investing Cash Flow
14.00
+111.18%
-125.26
-588.59%
25.64
+1249.64%
-2.23
Cash Flow From Continuing Investing Activities
14.00
+111.18%
-125.26
-588.59%
25.64
+1249.64%
-2.23
Net PPE Purchase And Sale
-1.18
-46.41%
-0.81
-151.71%
-0.32
+85.61%
-2.23
Purchase Of PPE
-1.18
-46.41%
-0.81
-151.71%
-0.32
+85.61%
-2.23
Capital Expenditure
-1.18
-46.41%
-0.81
-151.71%
-0.32
+85.61%
-2.23
Net Investment Purchase And Sale
15.19
+112.20%
-124.45
-2589.06%
5.00
0.00
Purchase Of Investment
-269.51
-35.81%
-198.45
0.00
—
Sale Of Investment
284.70
+284.73%
74.00
+1380.00%
5.00
0.00
Net Other Investing Changes
—
—
20.96
—
Financing Cash Flow
30.43
-83.47%
184.07
+99.03%
92.48
+39.01%
66.53
Cash Flow From Continuing Financing Activities
30.43
-83.47%
184.07
+99.03%
92.48
+39.01%
66.53
Net Issuance Payments Of Debt
-0.06
-17.31%
-0.05
-79.31%
-0.03
-2800.00%
-0.00
Repayment Of Debt
-0.06
-17.31%
-0.05
-79.31%
-0.03
-2800.00%
-0.00
Long Term Debt Payments
-0.06
-17.31%
-0.05
-79.31%
-0.03
-2800.00%
-0.00
Net Long Term Debt Issuance
-0.06
-17.31%
-0.05
-79.31%
-0.03
-2800.00%
-0.00
Net Common Stock Issuance
30.38
-83.98%
189.59
+105.31%
92.34
0.00
Proceeds From Stock Option Exercised
0.35
-79.12%
1.68
+897.62%
0.17
+130.14%
0.07
Net Other Financing Charges
-0.24
+96.63%
-7.14
—
—
Changes In Cash
-32.74
-177.63%
-11.79
-117.68%
66.70
+481.14%
11.48
Beginning Cash Position
136.93
-7.93%
148.72
+81.32%
82.02
+16.27%
70.54
End Cash Position
104.18
-23.91%
136.93
-7.93%
148.72
+81.32%
82.02
Free Cash Flow
-78.36
-9.73%
-71.41
-38.01%
-51.74
+6.01%
-55.05
Interest Paid Supplemental Data
0.01
-58.33%
0.01
+0.00%
0.01
+500.00%
0.00
Amortization Of Securities
-4.54
-87.52%
-2.42
-2203.81%
-0.10
0.00
Common Stock Issuance
30.38
-83.98%
189.59
+105.31%
92.34
0.00
Issuance Of Capital Stock
30.38
-83.98%
189.59
+105.31%
92.34
+38.95%
66.46
Net Preferred Stock Issuance
—
—
0.00
-100.00%
66.46
Preferred Stock Issuance
—
—
0.00
-100.00%
66.46
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category